Physician profile
James Rollins
NPI 1346238599
$9,342.19
in general payments reported to CMS, 2019-2025
11 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,304 · 2020: $225 · 2021: $1,886 · 2022: $1,324 · 2023: $1,567 · 2024: $2,022 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Travel and Lodging: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.84 |
| Travel and Lodging | $1,942.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $8,332.70 | 2019-2025 | Blueprint Patient Specific Instrumentation, Inspace, Mako |
| Depuy Synthes Sales INC. | $367.55 | 2021-2023 | Actis, Na, Tfn-Advance |
| Smith+Nephew, INC. | $303.17 | 2021-2024 | Pico 7 |
| Zimmer Biomet Holdings, INC. | $108.62 | 2023-2024 | Rosa, Persona, Alliance |
| Endo Pharmaceuticals INC. | $68.79 | 2020-2022 | |
| Dynasplint Systems INC. | $63.58 | 2021 | |
| Horizon Therapeutics Plc | $26.94 | 2020-2021 | |
| Solventum Corporation | $19.78 | 2025 | Prevena, V.A.C.Ulta |
| Davol INC. | $19.08 | 2025 | Arista |
| Vertex Pharmaceuticals Incorporated | $17.89 | 2025 | |
| Abbott Laboratories | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.